Ranbaxy in alliance with novavax to step in to

manufacture and market Clarithromycin XL 1000 mg tablets.
-Ranbaxy in alliance with Novavax to step in to biotech sector
-Ranbaxy Laboratories Ltd enters into collaborative agreement with
National Chemical Laboratories, Pune and Department of Science &
Technology in the area of New Drug Discovery.
- On May 24, 2005 launches its approved generic formulation of
Clarithromycin immediate release (IR) tablets, 250 mg and 500 mg, in
the US markets.
-Ranbaxy's Joint Venture with Nippon Chemiphar Ltd launches Vogseal
0.2mg & 0.3mg tablets for Diabetes
-Ranbaxy sets up additional manufacturing facility in Malaysia
-Ranbaxy opens third state of the art R&D facility on Gurgaon campus
-Company has splits its Face value of Shares from Rs 10 to Rs 5
2006
-Ranbaxy Laboratories enters into a strategic alliance with Zenotech
-Ranbaxy ties up with Ipca to tap US market
-Ranbaxy signs licensing agreement with Swiss Company Debiopharm, for
NCE Drug in the Gastroenterology Segment
-Ranbaxy signs licensing agreement with Swiss Company Debiopharm, for
NCE Drug in the Gastroenterology Segment.

-Ranbaxy Appoints Atul Sobti as COO.
-Ranbaxy Laboratories Ltd has announced that the Company has entered
into a collaborative agreement with the Department of Science &
Technology (DST), Government of India, New Delhi, in the area of New
Drug Discovery Research (NDDR).
-Ranbaxy granted final USFDA approval to Market Simvastatin 5, 10, 20
& 40 MG Tablets.
2007
-Ranbaxy Laboratories Ltd and GlaxosmithKline (GSK) on February 06,
2007 have signed a new multiyear R&D agreement that modifies and
expands the terms of their strategic alliance established in 2003 to
provide the Company expanded drug-development responsibilities and
further financial opportunities.
- Ranbaxy unveils asthma inhalation capsules.
- Ranbaxy Laboratories Ltd has received final approval from the U.S.
Food and Drug Administration (FDA) to manufacture and market
Amlodipine Besylate Tablets, 2.5 mg (base), 5 mg (base) and 10 mg
(base).
- Ranbaxy Laboratories Ltd on August 22, 2007 has the launch of
Roliflo OD (combination of Tamsulosin and Tolterodine) brand in the
Indian market for the management of bladder outlet obstruction with
concomitant overactive bladder, a chronic urological disorder. This
is a Novel Drug Delivery System (NDDS) product which is being
introduced for the first time in India.
2008

-Ranbaxy Laboratories on July 28 said it has launched the generic
version of Omeprazole capsules, used in the treatment of acid related
diseases in the US healthcare system.
2009
- Canada approves Ranbaxy's anti-hypertension drug
- Daiichi launched Ranbaxy drugs in Japan
-Ranbaxy subsidiary makes a deal with German health insurer
- Ranbaxy launched Daiichi Sankyo's innovative antihypertensive
drugs
2010
- Ranbaxy Laboratories Limited (Ranbaxy) has launched a New Chemical
Entity (NCE), Lulifin (Luliconazole), in the Indian Dermatology
market. This follows a strategic in-licensing agreement with Summit
Pharmaceuticals International Corporation, Japan (SPI) allowing
Ranbaxy, exclusive marketing rights, for India, 7'he introduction of
this NCE, significantly strengthens Ranbaxy's presence in the
Dermatological segment,
- Ranbaxy Laboratories has entered into an agreement with US-based
Pfenex Inc for developing biosimilars. Biosimilars are drugs which